Patient-Donor Matched Allogeneic Materials

We help to identify and source critical human leukocyte antigen (HLA)-matched donated materials for the treatment of specific patients.

A series of colored, oval graphics, and one photo of two scientists in lab coats discussing the contents of a screen.

Patient-Donor Matched Allogeneic Materials

We help to identify and source critical human leukocyte antigen (HLA)-matched donated materials for the treatment of specific patients.

Finding the best match for each patient

Working with developers and clinical sites, we help to find materials for therapies that rely on a specific donor or cord blood unit that is matched to a specific patient at a one-to-one ratio. NMDP BioTherapies leverages decades of experience working with transplant centers alongside cell and gene therapy expertise to meet regulatory and developer needs. We also offer search strategy advice to clinical sites interested in consulting with us to select the best possible match that complies with therapy-specific requirements.

NMDP Pattern

Leveraging extensive networks

Our domestic transplant center network is wide, and includes many of the most renowned hospitals in the United States. After years of established relationships with these centers, our protocols and systems — such as our donor and cord blood search applications — are part of their workflow for locating the best allogeneic match for their patients.

Additionally, we manage an apheresis center network to assist in high quality collection. We provide apheresis center staff specific training for compliance with protocol requirements, to ensure our partners receive materials that meet their needs.

A large selection of matched materials

We maintain a large, diverse donor registry and cord registry that provides a high likelihood of finding a match for patients while complying with any protocol requirements for donor attributes. Options include:

Checkmark icon

Mobilized HPC(A) (hematopoietic progenitor cells by apheresis) for direct infusion

Checkmark icon

HPC(A) as cellular starting material for further manufacture

Checkmark icon

Cord blood as cellular starting material for further manufacture

Checkmark icon

Nonmobilized mononuclear cells as cellular starting material for further manufacture

Explore NMDP solutions

Meet manufacturing supply needs: access clinical-grade leukopaks for cell therapy manufacturing, with customizable options to meet a variety of needs.